DISEASE SCANNER

Global Incurable Diseases Tracker

Back to Globe
Orthopedic Condition

Ankylosing Spondylitis

MODERATE

A chronic inflammatory arthritis primarily affecting the axial skeleton (spine and sacroiliac joints), causing pain, stiffness, and potential fusion. A form of spondyloarthritis. Strong association with HLA-B27. Onset typically in young adulthood.

Global Affected

15.0M

Countries

111

Symptoms

Chronic lower back pain
Morning stiffness >30 min
Improved with exercise
Sacroiliac joint pain
Spinal fusion (bamboo spine)
Reduced spinal mobility
Peripheral arthritis
Enthesitis
Uveitis
Fatigue

Treatment Options

NSAIDs (first-line)
TNF inhibitors
IL-17 inhibitors
JAK inhibitors
Sulfasalazine
Methotrexate
Corticosteroids (local)
Physical therapy
Exercise programs
Surgery (rarely)

Risk Factors

1HLA-B27 positivity
2Family history
3Male gender
4Age 17-45
5Inflammatory bowel disease
6Psoriasis
7Reactive arthritis history

Diagnostic Methods

  • 1Clinical criteria (ASAS)
  • 2X-rays of sacroiliac joints
  • 3MRI of sacroiliac joints and spine
  • 4HLA-B27 testing
  • 5Blood tests (ESR, CRP)
  • 6Assessment for uveitis
  • 7Assessment for IBD

Prognosis

Good functional outcome with early anti-TNF therapy. Disease-modifying therapy slows radiographic progression. 10-20% have severe disability with spinal fusion. Uveitis affects 30-40%; usually responsive to topical steroids. Cardiac involvement (aortitis) rare but serious. Osteoporosis common in spine; fracture risk increased. Regular exercise maintains mobility. Biologic therapy has transformed outcomes; 70-80% achieve ASAS40 response. Smoking cessation important. Spinal surgery rarely needed.

Prevention

  • No primary prevention
  • Early diagnosis and treatment
  • Regular exercise
  • Smoking cessation
  • Good posture
  • Ergonomic workplace
  • Screening for associated conditions

Research Status

TNF inhibitors (infliximab, etanercept, adalimumab, golimumab, certolizumab) and IL-17 inhibitors (secukinumab, ixekizumab) highly effective. JAK inhibitors (tofacitinib, upadacitinib) approved. Biosimilars improving access. MRI early detection.

Sources

  • https://www.cdc.gov/
  • https://www.hematology.org/education/patients
  • https://www.ncbi.nlm.nih.gov/books
  • https://rarediseases.org/rare-diseases

Medical Disclaimer

This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.